Phase 1, Multicenter, Open-Label, Multiple-Dose Study of DS-8201a to Assess the Effect on the QT Interval, and Pharmacokinetics in Subjects with HER2-Expressing Metastatic and/or Unresectable Breast Cancer
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 19 Nov 2019
Price : $35 *
At a glance
- Drugs Trastuzumab-deruxtecan (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Daiichi Sankyo Company
- 19 Nov 2019 According to a Daiichi Sankyo Company media release, data from this study will be presented at the 2019 San Antonio Breast Cancer Symposium (#SABCS19), December 10-14, 2019 in San Antonio, Texas.
- 30 Sep 2018 Planned primary completion date changed from 1 Sep 2018 to 1 Nov 2018.
- 26 Sep 2018 Planned End Date changed from 30 Sep 2018 to 31 Mar 2020.